ASP Isotopes (NASDAQ:ASPI) CEO Paul Elliot Mann Sells 83,758 Shares of Stock

ASP Isotopes Inc. (NASDAQ:ASPI) CEO Paul Elliot Mann sold 83,758 shares of the stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $8.29, for a total value of $694,353.82. Following the completion of the transaction, the chief executive officer directly owned 9,663,424 shares in the company, valued at $80,109,784.96. This trade represents a 0.86% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Paul Elliot Mann also recently made the following trade(s):

• On Wednesday, June 3rd, Paul Elliot Mann sold 83,759 shares of ASP Isotopes stock. The shares were sold at an average price of $7.76, for a total value of $649,969.84.

ASP Isotopes Stock Performance

NASDAQ:ASPI opened at $7.55 on Thursday. The firm has a market capitalization of $950.55 million, a PE ratio of -3.63 and a beta of 3.42. The business’s fifty day moving average price is $5.44 and its 200 day moving average price is $5.87. The company has a debt-to-equity ratio of 0.69, a current ratio of 4.39 and a quick ratio of 4.37. ASP Isotopes Inc. has a 12 month low of $3.92 and a 12 month high of $14.49.

ASP Isotopes (NASDAQ:ASPI) last posted its earnings results on Wednesday, May 20th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.06. The firm had revenue of $8.36 million for the quarter, compared to analyst estimates of $3.68 million. ASP Isotopes had a negative return on equity of 112.46% and a negative net margin of 644.40%.

Analyst Ratings Changes

ASPI has been the subject of several research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of ASP Isotopes in a research note on Friday, March 27th. Canaccord Genuity Group restated a “buy” rating and issued a $11.00 price objective on shares of ASP Isotopes in a research report on Tuesday, April 14th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, ASP Isotopes has a consensus rating of “Hold” and a consensus price target of $13.00.

Hedge Funds Weigh In On ASP Isotopes

Hedge funds have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of ASP Isotopes by 9.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,613 shares of the company’s stock worth $148,000 after purchasing an additional 2,709 shares during the last quarter. Rhumbline Advisers raised its position in shares of ASP Isotopes by 20.9% during the 2nd quarter. Rhumbline Advisers now owns 78,994 shares of the company’s stock worth $581,000 after purchasing an additional 13,668 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of ASP Isotopes during the 2nd quarter worth approximately $178,000. New York State Common Retirement Fund raised its holdings in ASP Isotopes by 418.2% in the 2nd quarter. New York State Common Retirement Fund now owns 17,100 shares of the company’s stock valued at $126,000 after acquiring an additional 13,800 shares during the last quarter. Finally, Invesco Ltd. raised its holdings in ASP Isotopes by 2,205.0% in the 2nd quarter. Invesco Ltd. now owns 471,219 shares of the company’s stock valued at $3,468,000 after acquiring an additional 450,776 shares during the last quarter. 16.80% of the stock is currently owned by hedge funds and other institutional investors.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.